Abstract
The efficacy of CTX as initial chemotherapy in advanced ovarian carcinoma has been well documented. Its apparently greater response rate when administered in a high-dose bolus has prompted its application to patients who have failed on melphalan. Piver et al. reported only one partial response lasting 1 month among seven patients with ovarian cancer refractory to alkylating drug therapy. Three of his patients had received low-dose CTX in combination with actinomycin D and 5-FU or methotrexate prior to receiving high-dose CTX. Although none of our patients had received prior CTX, the response rate was comparable (two of ten patients, 20%) with no complete responses. Toxicity from this drug regimen was considerable. In our study four of 13 patients (30%) had severe or life-threatening leukopenia with two of four (50%) complicated by septicemia. In Piver's group six of eight patients (75%) had severe leukopenia with five manifesting septicemia. It is clear that the risks of high-dose bolus CTX therapy for ovarian carcinoma resistant to melphalan outweigh the potential benefits.
| Original language | English |
|---|---|
| Pages (from-to) | 1369-1371 |
| Number of pages | 3 |
| Journal | Cancer Treatment Reports |
| Volume | 61 |
| Issue number | 7 |
| State | Published - Dec 1 1977 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after failure on melphalan. / Twiggs, L. B.; Morrow, C. P.
In: Cancer Treatment Reports, Vol. 61, No. 7, 01.12.1977, p. 1369-1371.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after failure on melphalan
AU - Twiggs, L. B.
AU - Morrow, C. P.
PY - 1977/12/1
Y1 - 1977/12/1
N2 - The efficacy of CTX as initial chemotherapy in advanced ovarian carcinoma has been well documented. Its apparently greater response rate when administered in a high-dose bolus has prompted its application to patients who have failed on melphalan. Piver et al. reported only one partial response lasting 1 month among seven patients with ovarian cancer refractory to alkylating drug therapy. Three of his patients had received low-dose CTX in combination with actinomycin D and 5-FU or methotrexate prior to receiving high-dose CTX. Although none of our patients had received prior CTX, the response rate was comparable (two of ten patients, 20%) with no complete responses. Toxicity from this drug regimen was considerable. In our study four of 13 patients (30%) had severe or life-threatening leukopenia with two of four (50%) complicated by septicemia. In Piver's group six of eight patients (75%) had severe leukopenia with five manifesting septicemia. It is clear that the risks of high-dose bolus CTX therapy for ovarian carcinoma resistant to melphalan outweigh the potential benefits.
AB - The efficacy of CTX as initial chemotherapy in advanced ovarian carcinoma has been well documented. Its apparently greater response rate when administered in a high-dose bolus has prompted its application to patients who have failed on melphalan. Piver et al. reported only one partial response lasting 1 month among seven patients with ovarian cancer refractory to alkylating drug therapy. Three of his patients had received low-dose CTX in combination with actinomycin D and 5-FU or methotrexate prior to receiving high-dose CTX. Although none of our patients had received prior CTX, the response rate was comparable (two of ten patients, 20%) with no complete responses. Toxicity from this drug regimen was considerable. In our study four of 13 patients (30%) had severe or life-threatening leukopenia with two of four (50%) complicated by septicemia. In Piver's group six of eight patients (75%) had severe leukopenia with five manifesting septicemia. It is clear that the risks of high-dose bolus CTX therapy for ovarian carcinoma resistant to melphalan outweigh the potential benefits.
UR - http://www.scopus.com/inward/record.url?scp=0017590062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017590062&partnerID=8YFLogxK
M3 - Article
C2 - 589602
AN - SCOPUS:0017590062
VL - 61
SP - 1369
EP - 1371
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 7
ER -